Market News AIOpen the app

INSM stock news · Insmed

Stories about Insmed (INSM) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for INSM

Follow Insmed (INSM) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for INSM
Free on the App Store and Google Play, or on the web.
  1. Nov 20, 2026, 11:34 AM ET · Market

    Analysts at Renta 4 Banco looked into how Sanofi buying Insmed could fit with its plans.

    Neutral

    Sanofi is exploring a possible purchase of Insmed, but no offer has been made. The report gives no offer terms or confirmed deal, so it does not change Insmed's outlook.

  2. Nov 19, 2026, 2:05 PM ET · Market

    Sanofi is looking at buying Insmed, which has caused Insmed's stock price to jump.

    Good for INSM

    Reports say Sanofi is evaluating a possible takeover of Insmed, raising the chance of a buyer. The report is unconfirmed and gives no agreed price, but the takeover interest favors Insmed.

  3. Nov 19, 2026, 11:34 AM ET · Market

    Sanofi is looking into buying Insmed as part of its growth plans.

    Neutral

    Insmed is named as a possible takeover target, but no offer or agreement is reported. That leaves no confirmed change to Insmed's business outlook.

  4. Oct 20, 2026, 7:09 AM ET · Market

    Insmed Inc. is changing its directors and officers, adding Paul Hudson and Utpal Koppikar to the board.

    Neutral

    Insmed added 2 experienced biopharma leaders to its board. Their backgrounds may help oversight, but the filing reports no business change and adds director pay and stock awards, leaving the outlook unchanged.

  5. Oct 5, 2026, 7:52 AM ET · Results

    Insmed shares the details from its earnings call for the second quarter of 2026.

    Good for INSM

    Insmed reported $309 million in Brensocatib sales, up 49% from the prior quarter, and raised its 2026 sales forecast, pointing to a stronger outlook.